Indeed, the distinction of de novo AML with BCR::ABL1 from initial myeloid blast phase of CML (CML-BP) can be challenging although patient medical history and a few biological characteristics may help to differentiate them. This evidence concerns the gene ABL1 and acute myeloid leukemia.